Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma
Joseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, Juan Carlos Ramos, Richard F Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H Henry, Lee Ratner, Ethel Cesarman, Amy Chadburn, Ronald Mitsuyasu, Joseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, Juan Carlos Ramos, Richard F Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H Henry, Lee Ratner, Ethel Cesarman, Amy Chadburn, Ronald Mitsuyasu
Abstract
Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with HIV-associated DLBCL and high-grade lymphoma treated with 4-6 cycles of EPOCH plus rituximab based a response-adapted treatment strategy. 106 evaluable patients with HIV-associated DLBCL or high-grade CD20-positive non-Hodgkin's lymphoma were randomized to receive rituximab (375 mg/m2) given either concurrently prior to each infusional EPOCH cycle, or sequentially (weekly for 6 weeks) following completion of EPOCH. EPOCH consisted of a 96-hour IV infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles. Patients received 2 additional cycles of therapy after documentation of a complete response (CR) by computerized tomography after cycles 2 and 4. 64 of 106 evaluable patients (60%, 95% CI 50%, 70%) had a CR in both treatment arms. The 2-year event-free survival (EFS) rates were similar in the 24 patients with CR who received 4 or fewer EPOCH cycles (78%, 95% confidence intervals [55%, 90%]) due to achieving a CR after 2 cycles, compared with those who received 5-6 cycles of EPOCH (85%, 95% CI 70%, 93%) because a CR was first documented after cycle 4. A response-adapted strategy may permit a shorter treatment duration without compromising therapeutic efficacy in patients with HIV-associated lymphoma treated with EPOCH plus rituximab, which merits further evaluation in additional prospective trials. Clinical Trials.gov identifier NCT00049036.
Figures
References
- Tilly H, Gomes da Silva M, Vitolo U, et al. . Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):116-125.
- Zelenetz AD, Abramson JS, Advani RH, et al. . NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
- Wasterlid T, Biccler JL, Brown PN, et al. . Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large Bcell lymphoma: a Nordic Lymphoma Group population-based study. Ann Oncol. 2018; 29(8):1882-1883.
- Poeschel V, Held G, Ziepert M, et al. . Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the FLYER trial of the DSHNHL/GLA. Blood. 2018;132 (Suppl 1):781.
- Sparano JA, Weller E, Nazeer T, et al. . Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non- Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002;100(5):1634-1640.
- Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non- Hodgkin's lymphoma: evidence for a schedule- dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993;11(6):1071-1079.
- Wilson WH, Bryant G, Bates S, et al. . EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(8):1573-1582.
- Wilson WH, Grossbard ML, Pittaluga S, et al. . Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
- Little RF, Pittaluga S, Grant N, et al. . Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653-4659.
- Sparano JA, Wiernik PH, Hu X, et al. . Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996;14(11):3026-3035.
- Sparano JA, Lee S, Chen MG, et al. . Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIVassociated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol. 2004;22(8):1491-1500.
- Spina M, Jaeger U, Sparano JA, et al. . Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891-1897.
- Sparano JA. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol. 2007;19(5):458-463.
- Sparano JA, Lee JY, Kaplan LD, et al. . Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-3016.
- Kaplan LD, Lee JY, Ambinder RF, et al. . Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.
- Cheson BD, Horning SJ, Coiffier B, et al. . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4): 1244.
- Barta SK, Joshi J, Mounier N, et al. . Central nervous system involvement in AIDS-related lymphomas. Br J Haematol. 2016;173(6):857-866.
- Ngongondo M, Kang M, Umbleja T, et al. . Early progression and immune reconstitution inflammatory syndrome during treatment of mild-to-moderate Kaposi sarcoma in low-resource settings: incidence, longterm outcomes and effects of early chemotherapy. 17th International Conference on HIV AIDS, Bethesda, MD, USA. October 21-22, 2019.
- Dunleavy K, Pittaluga S, Shovlin M, et al. . Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
- Dunleavy K, Noy A, Abramson JS, et al. . Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DAEPOCH- R. Blood. 2015;126(23):342-342.
- Barta SK, Xue X, Wang D, et al. . Treatment factors affecting outcomes in HIV- associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262.
- Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS- related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009;27(30):5039-5048.
- Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
- Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large Bcell lymphoma. N Engl J Med. 2018;378(15): 1396-1407.
- Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma -comparison with CT. Leuk Lymphoma. 2000;39(5-6):543-553.
- Spaepen K, Stroobants S, Dupont P, et al. . Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non- Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
- Haioun C, Itti E, Rahmouni A, et al. . [18F]fluoro- 2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4): 1376-1381.
- Dupuis J, Itti E, Rahmouni A, et al. . Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
- Carr R, Fanti S, Paez D, et al. . Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55(12):1936-1944.
- Dabaja BS, Vanderplas AM, Crosby-Thompson AL, et al. . Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015;121(7):1032-1039.
- Mamot C, Klingbiel D, Hitz F, et al. . Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with RCHOP- 14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523-2529.
- Swinnen LJ, Li H, Quon A, et al. . Responseadapted therapy for aggressive non- Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170(1):56-65.
- Duhrsen U, Muller S, Hertenstein B, et al. . Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024-2034.
- Casasnovas RO, Ysebaert L, Thieblemont C, et al. . FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315-1326.
- Mhlanga JC, Durand D, Tsai HL, et al. . Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Med Mol Imaging. 2014;41(4):596-604.
Source: PubMed